Semaglutide treatment reduced the number of CD16/32+ microglia and C3d+/GFAP+ A1 astrocytes and subsequently reduced brain infarct volume, improved neurobehavioral outcomes, reduced neuroinflammation, and attenuated BBB disruption in tMCAO mice. The gene discussed is GFAP; the disease is brain infarction.